Rebus Holdings Inc (RBSH)

[AAAAMHIM]

NSPX ADDED AND ADDING. You guys are crazy. Anyone can go on any board and scream REVERSE SPLIT OR INCREASE IN A/S! They've been around 17 years and have only had a REVERSE split TWICE!!! And both were TINY, under 35:1 unlike 99.999% of pennystocks that have MASSIVE 200:1- 10,000:1 reverse splits. Increase of A/S???!! THEY'VE NEVER INCREASED the A/S.

Nothing has changed here apart from the fact that traders who weren't allowed to sell because the O/S wasn't updated are now allowed to and they GAVE AWAY THEIR SHARES (many of those shares to me).

You know what else we figured out by the beautiful 10k??? THE SHARES ARE MAXED!!! FLOAT LOCKDOWN candidate of the year. MATH FOLKS. FACT not an opinion, shares are MAXED.

Another fact is that it only has 150 million A/S!!! One of the tiniest A/S vs price out of 10,000+ stocks in the OTC. Not an opinion. Its a FACT

What else did we learn from the 10k? THEY ARE SEEKING ACQUISITIONS
In-licensing or Acquisition Strategy
 
In addition to the development of our current product candidates, we have initiated an in-licensing or acquisition strategy to further expand our product pipeline. Our in-licensing strategy consists of evaluating early clinical or late preclinical stage opportunities in therapeutic areas that can benefit from our current product candidates or core expertise in drug development. We believe that this element of our corporate strategy could diversify some of the risks inherent in focusing on limited therapeutic areas and could increase our probability of commercial success.



Asset Acquisition Strategy
 
In addition to the anticipated development of our current product candidates once we receive adequate capital to resume our operations, we have initiated a search for suitable pre-clinical and clinical assets to further expand our product pipeline. We are looking for assets with the potential to be complimentary to our current technologies or that could benefit from our development experience with the goal of developing such candidates for commercialization. We believe that this element of our corporate strategy could provide new opportunities for product development and diversify risks inherent in potentially focusing on a limited product portfolio and therapeutic areas, thus potentially increasing our probability of commercial success.
In-licensing or Acquisition Strategy
 
In addition to the development of our current product candidates, we have initiated an in-licensing or acquisition strategy to further expand our product pipeline. Our in-licensing strategy consists of evaluating early clinical or late preclinical stage opportunities in therapeutic areas that can benefit from our current product candidates or core expertise in drug development. We believe that this element of our corporate strategy could diversify some of the risks inherent in focusing on limited therapeutic areas and could increase our probability of commercial success.
When appropriate, we will continue to seek patent protection for inventions in our core technologies and in ancillary technologies that support our core technologies or which we otherwise believe will provide us with a competitive advantage. We will accomplish this by filing and maintaining patent applications for discoveries we make, either alone or in collaboration with scientific collaborators and strategic partners. Typically, we plan to file patent applications in the United States and, for LNC-003, in the Patent Cooperation Treaty (PCT). In addition, we plan to obtain licenses or options to acquire licenses to patent filings from other individuals and organizations that we anticipate could be useful in advancing our research, development and commercialization initiatives and our strategic business interest.   
  
Development Strategy
 
While we curtailed our operations in February 2018 due to our cash position, in the event that we are able to raise sufficient capital to execute our clinical and pre-clinical development strategy, we anticipate that under the planning and direction of key personnel, we expect to outsource all our nonclinical development and manufacturing, and the majority of our clinical development activities to contract research organizations (CROs) and contract manufacturing organizations (CMOs). Our contract CROs and CMOs are required to comply with federal, state and United States Food and Drug Administration or FDA regulations including Good Manufacturing Practices (cGMP), Good Clinical Practices (GCP), and Good Lab Practices (GLP).

OH DID YOU GUYS FORGET ABOUT THE TECHNOLOGY? Keep letting people who sit on this boards all day and no where else fool you into believing theres nothing here.

NOTHING HAS CHANGED to the downside, only to the upside.
 
Our Technology
 
We have what we believe to be a robust intellectual property portfolio covering proprietary A2A agonists (LNC-001, see below), A2B antagonists (LNC-002, see below), and dual A2A/A2B antagonists (LNC-003, see below). We also have a substantial catalog of synthesized compounds, specifically A2A agonists and A2B antagonists that require further characterization and testing for potential clinical candidates. We believe that our proprietary dual A2A/A2B antagonists have great potential and should be further explored.
 
Patents and Proprietary Rights
 
Our success will likely depend upon our ability to preserve our proprietary technologies and operate without infringing the proprietary rights of other parties. However, we may rely on certain proprietary technologies and know-how that are not patentable or that we determine to keep as trade secrets. We protect our proprietary information, in part, using confidentiality agreements with our employees, consultants, significant scientific collaborators, and sponsored researchers that generally provide that all inventions conceived by the individual in the course of rendering services to us shall be our exclusive property.
 

4

 

 
The intellectual property underlying our technology is covered by certain patents and patent applications previously owned by Lewis and Clark Pharmaceuticals, Inc. (LNC) and now fully owned by the Company. All of the LNC intellectual property has been assigned to LNC, a fully owned subsidiary of the Company.
 


THERE IS NOT GOING TO BE ANY REVERSE SPLIT. THEY JUST DID ONE.


KEEP FEEDING ME. When I'm finally filled, I'll bring in the calvary. PERIOD.


$NSPX .0082 on the ask! 0082 on the ask!!! FREE MONEY You have to be CRAZY to ignore 0055 on the ask. Let me break this down VERY SLOWLY

$NSPX. 0082?!! Only 150 million A/S? Over or near 140 million O/S??! #BIOTECH cancer stock with BRAIN CANCER DRUG?! GUARANTEE THAT SHE WILL BE HIGHER than this price on a mathematical level, in my honest opinion. Relation of shares held vs share structure and price highly favors the trader her imo. Learn the dance ???????????????

NSPX DD Package:

1. Company Profile:
Inspyr Therapeutics, Inc., formerly Genspera, Inc is an integrated biopharmaceutical company focused on the development of novel therapies to treat cancer, inflammation, and other serious diseases. Through a merger with Lewis and Clark Pharmaceuticals, Inc., Inspyr has a proprietary, industry-leading adenosine receptor modulator (ARM) technology platform and a broad pipeline of novel therapies. Inspyr’s pipeline includes Mipsagargin, a pro-drug that has completed a phase 2 clinical trial for the treatment of liver cancer, and the ARM preclinical programs consisting of A2A, A2B, and dual A2A/A2B receptor antagonists for the treatment of cancer and A2A agonists for the treatment of inflammatory and other serious diseases. The Company has fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia, where a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation, plasma concentration analysis, assay development, and toxicology.

2. MIPSAGARGIN- Inspyr’s drug that can potentially cure various cancers-

MUST WATCH videos about Mipsagargin:

Intro into Mipsagargin by Inspyr(formerly Genspera):

https://t.co/U0xEcckSSr

NSPX in the News- Mipsagargin Breakthrough Drug- Potential replacement for chemotherapy:

https://t.co/8gXqmHM1Z8

Physicians React to Phase 2 Update on GenSpera’s Mipsagargin in Hepatocellular Carcinoma at ASCO GI:

https://t.co/SRytLq1mww

Mipsagargin latest update as of June 2018 (with other patent info):
https://t.co/II3si8WiI2

https://t.co/KIDcRgOZrv

Q/A with the Doctor behind Mipsagargin:
https://t.co/hAs4i4NPbh

3. Meet our CEO- Chris Lowe:

https://t.co/UCTvhMYOQt

Chris Lowe joined FLG in 2014, serves on the Firm’s Management Committee and was elected Co-Managing Partner in 2018. Chris has over 15 years of senior management experience as President, CBO and CFO of various private and public life sciences, medical technology, and technology companies. Additionally, he has served as a member of the Board of Directors of both public and private companies, and has chaired their respective Audit Committees and Compensation Committees. Chris helps companies succeed by assisting them with corporate and financial strategy, including early stage financing, successive fundraising and IPOs, public company advising and Wall Street communications, licensing transactions, M&A, restructurings and coaching at every level of the C-Suite. In particular, he excels at helping companies navigate the challenges of accessing capital, M&A, licensing, restructurings and exits.
During his career as a C-level executive, Chris has successfully raised over $500M in private and public financings, completed over $1.0B in M&A transactions, negotiated over $300M in debt instruments for companies, and has overseen three SOX-404 implementations. As VP and CAO, he drove a parallel M&A and IPO path resulting in the sale of Peninsula Pharmaceuticals to Johnson & Johnson for over $300M in 2005, including the design of a tax efficient spinout for assets which were undervalued by Johnson & Johnson. As CFO of Asthmatx, a medical technology company, he actively drove strategic supply negotiations and led the parallel M&A and IPO process resulting in a $50M strategic investment from Olympus Medical and ultimately the sale of the company to Boston Scientific in a deal valued at approximately $400M. As its Chief Financial Officer, he also took Anthera Pharmaceuticals, a pharmaceutical development company, public in 2010 during the height of the financial crisis, raising over $300M in both the private and public markets during his tenure.
Prior to joining FLG, Chris recently served as a strategy, financial and management consultant to several public and private companies, assisting them with financings, market due diligence, Wall Street communications, and exits.
Chris earned his B.S. from California Polytechnic State University – San Luis Obispo, and a MBA from St Mary’s University. Chris currently sits on the Board of Directors of the following public and private companies: Hansen Medical (NASDAQ: HNSN; 2006-present); Pacific Pharmaceuticals (private; 2010-present); and Career Closet (Non Profit; 2009-present).

4. Most recent NEWS with potential 12 Million Licensing deal with Ridgeway Therapeutics:

Inspyr to License Oncology Related Compounds to Ridgeway Therapeutics Inc.
9/17/18, 8:00 AM
WESTLAKE VILLAGE, Calif., Sept. 17, 2018 Inspyr Therapeutics announced today that it has entered into an agreement with Ridgeway Therapeutics Inc. in which Ridgeway will license and assume control of certain assets relating to Inspyr's oncology development programs, including intellectual property rights relating to adenosine antagonists owned by Inspyr.
Adenosine receptors have a variety of functions in the body that are expressed through four subtypes (A1, A2A, A2B, and A3). The adenosine A2 receptor subtypes (A2R) are of particular interest as potential targets for the treatment of cancer. Extremely high levels of adenosine are found locally in the tumor microenvironment. These have a direct immunosuppressive effect on T-cells and other cell types that would otherwise attack and kill cancer cells. Inhibition of the A2R has the potential to reverse these immunosuppressive effects.
Inspyr and Ridgeway will collaborate on certain aspects of development which will include a minimum level of purchased services by Ridgeway within 18 months of this transaction. In addition, Inspyr is eligible for approximately $12 million in success-based milestones from the Transaction. Inspyr is also entitled to receive royalties on all commercial https://t.co/k39edFqAhz the event Ridgeway sub-licenses these assets, Inspyr is entitled to share in the proceeds of any future transaction.
https://t.co/OOWZi61mN8

***This licensing deal does not cover Mipsagargin so there may be another separate deal in the works....

5. Past News Releases or Articles of Significance:

1. Oct 23 2017- Inspyr Therapeutics Announces Research Collaboration with the National Institutes of Health
https://t.co/6qRi2x1Nzr

2. Oct 4 2017- Inspyr Therapeutics Announces Research Collaboration with NYU Winthrop Hospital-Dr. Allison Reiss Initiates Pre-Clinical Study for Atherosclerosis
https://t.co/2LNmhqSLZb

3. Oct 2 2017- Inspyr Therapeutics Announces Research Collaboration with University of Virginia School of Medicine-Dr. Cirle Warren Initiates Pre-Clinical Study for Clostridium Difficile
https://t.co/PNBa2pvpuc

4. Sept 13 2017- Inspyr Therapeutics and Lewis and Clark Pharmaceuticals Complete Merger- Creating Integrated Company with Proprietary Platform, Broad Pipeline, and Significant Drug Development Expertise
https://t.co/5Q3SknTHBN

5. Sept 12 2017- Inspyr Therapeutics Announces Private Placement of Senior Convertible Debentures
https://t.co/eOYiEgNgjU

6. Aug 4 2016- Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
https://t.co/D7Ga4ZkM8n

7. Aug 1 2016- GenSpera Announces Name Change to Inspyr Therapeutics[b/]
https://t.co/iQ0dYbmM0y

8. June 9 2015- GenSpera And Cancer-Specific Hand Grenades
https://t.co/Vssbi18W70

9. March 30 2015- GenSpera Contends In The Prodrug Space, Reaching Phase 3
https://t.co/uvS32FzD0T

10. Feb 24 2015 - Genspera's Mipsagargin Phase 2 Results Impress
https://t.co/V7Uq8zJIBs

11. Jan 16 2015- ***GenSpera Announces Positive Phase II Data for Investigational Agent Mipsagargin-First-in-Class Agent is Well Tolerated in Liver Cancer Patients***
https://t.co/KyEwFJU3zz

6. Recent Inside significant stake by Hedge Fund Sabby Management:

NEW 13G Filing:
https://t.co/3hJG2DQITX

Sabby Management, LLC is an employee owned investment manager. The firm primarily provides its services to pooled investment vehicles. It invests in the public equity and alternative investment markets of the United States. The firm primarily invests in options. It also makes private investments in public equity. The firm employs a opportunistic and event-driven strategy to make its investments. It also employs fundamental and quantitative analysis. The firm invests in the healthcare sector, including the biotechnology and pharmaceutical sector. Sabby Management, LLC was formed on June 6, 2011 and is based in Upper Saddle River, New Jersey.

7. Share Structure:

O/S= 150 million
A/S=150,000,000
SHARES MAXED!
NSPX NSPX NSPX